Histone Demethylases

Histone demethylase inhibitors block the enzymes that remove methyl groups from lysine residues on histones. Lysine-specific demethylase 1 (LSD1) is a flavin-dependent amine oxidase that demethylates mono- and dimethylated lysine 4 of histone H3 (H3K4). The larger Jumonji C (JmjC) domain family uses iron and 2-oxoglutarate as cofactors, and some members also remove trimethyl marks. SP2509 and GSK2879552 are inhibitors of LSD1 used in chromatin and differentiation studies. GSK J1 targets two demethylases of lysine 27 on histone H3 (H3K27), Jumonji domain-containing protein 3 (JMJD3) and ubiquitously transcribed X-chromosome tetratricopeptide repeat protein (UTX). GSK-J4 is its cell-permeable ester, used for studies in intact cells. JIB-04 acts on several JmjC demethylases, and YUKA1 inhibits lysine-specific demethylase 5A (KDM5A).

Items 126-150 of 170

  • N19-0881
    Cat. No.
    A29314

    N19-0881

    N19-0881 is a selective inhibitor of KDM5A and KDM5B histone lysine demethylases, exhibiting potent activity with IC50 values of 0.013 μM and 0.002 μM, respectively. This compound demonstrates significant potential in the study of epigenetically dysregulated tumors, particularly in applications related to breast cancer research. Its oral bioactivity makes it an effective tool for investigating the role of histone modification in cancer biology and therapeutic development.

    Out of stock

    All 3 sizes
  • Bizine di(hydrochloride)
    Cat. No.
    A29317

    Bizine di(hydrochloride)

    Bizine di(hydrochloride) is a potent and selective inhibitor of the lysine-specific demethylase 1 (LSD1) enzyme, exhibiting a Ki value of 59 nM. This compound effectively modulates bulk histone methylation in cancer cells, making it valuable for epigenetic studies related to cancer biology. Additionally, Bizine di(hydrochloride) demonstrates neuroprotective effects, supporting its potential applications in neurological research.

    5 mg
    $90.00
    10 mg
    $150.00
    All 5 sizes
  • 3β-Acetoxyl-atractylenolide I
    Cat. No.
    A29318

    3β-Acetoxyl-atractylenolide I

    3β-Acetoxyl-atractylenolide I is a potent inhibitor of lysine-specific demethylase 1 (LSD1), demonstrating an IC50 of 57 μM. This compound has been shown to effectively block tumor growth, metastasis, and invasion across various cancer types. It is utilized in research focusing on prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia, and retinoblastoma.

    Out of stock

    All 3 sizes
  • GSK-J4 hydrochloride
    Cat. No.
    A29319

    GSK-J4 hydrochloride

    GSK-J4 hydrochloride is a potent dual inhibitor of the demethylases JMJD3 (KDM6B) and UTX (KDM6A), with IC50 values of 8.6 μM and 6.6 μM, respectively. This compound demonstrates significant inhibition of LPS-induced TNF-α production in human primary macrophages, with an IC50 of 9 μM. GSK-J4 hydrochloride serves as a cell-permeable proagent of GSK-J1 and is valuable for research into epigenetic regulation and inflammation-related pathways.

    1 mg
    $25.00
    2 mg
    $40.00
    All 8 sizes
  • KDM5-C70
    Cat. No.
    A29320

    KDM5-C70

    KDM5-C70 is a potent and cell-permeable pan-KDM5 histone demethylase inhibitor, derived from KDM5-C49 as an ethyl ester. It exhibits significant antiproliferative activity in myeloma cells, effectively increasing global levels of H3K4me3. KDM5-C70 is valuable for research exploring epigenetic regulation and its implications in cancer biology.

    2 mg
    $30.00
    5 mg
    $45.00
    All 9 sizes
  • GSK2879552 dihydrochloride
    Cat. No.
    A29321

    GSK2879552 dihydrochloride

    GSK2879552 dihydrochloride is a selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A). This compound exhibits potential antineoplastic activity, making it valuable in cancer research. Its ability to modify epigenetic regulation through LSD1 inhibition allows for exploration of therapeutic strategies in malignancies where LSD1 is implicated.

    1 mg
    $45.00
    2 mg
    $65.00
    All 8 sizes
  • KDOAM-25 citrate
    Cat. No.
    A29323

    KDOAM-25 citrate

    KDOAM-25 citrate is a selective inhibitor of histone lysine demethylases 5 (KDM5) with IC50 values of 71 nM, 19 nM, 69 nM, and 69 nM for KDM5A, KDM5B, KDM5C, and KDM5D, respectively. This compound is known to enhance global H3K4 methylation at transcriptional start sites, thereby influencing gene expression. Its activity contributes to the inhibition of proliferation in multiple myeloma MM1S cells, making it a valuable tool for research in epigenetics and cancer biology.

    5 mg
    $80.00
    10 mg
    $150.00
    All 7 sizes
  • TK-129
    Cat. No.
    A29326

    TK-129

    TK-129 is a potent inhibitor of KDM5B, exhibiting low toxicity and high affinity with an IC50 of 44 nM. By targeting KDM5B, TK-129 disrupts the KDM5B-associated Wnt signaling pathway, resulting in cardioprotective effects. This compound effectively reduces angiotensin II-induced activation of cardiac fibroblasts in vitro and mitigates isoprenaline-induced myocardial remodeling and fibrosis in vivo. TK-129 is valuable for research in cardiovascular disease mechanisms and therapeutic strategies.

    5 mg
    $125.00
    10 mg
    $210.00
    All 5 sizes
  • JMJD6-IN-1
    Cat. No.
    A29327

    JMJD6-IN-1

    JMJD6-IN-1 is a selective inhibitor of JMJD6, demonstrating an inhibition rate of 82% at a concentration of 10 μM. It effectively reduces the proliferation of MCF-7 and HCC4006 cancer cell lines, with IC50 values of 19.2 μM and 25.2 μM, respectively. This compound is suitable for research applications focused on cancer biology and the exploration of JMJD6’s role in tumorigenesis.

    1 mg
    $25.00
    5 mg
    $60.00
    All 7 sizes
  • KDM4C-IN-1
    Cat. No.
    A29328

    KDM4C-IN-1

    KDM4C-IN-1 is a potent inhibitor of the lysine demethylase KDM4C, exhibiting an IC50 of 8 nM. This compound has demonstrated significant biological activity by inhibiting the proliferation of HepG2 and A549 cancer cell lines, with IC50 values of 0.8 µM and 1.1 µM, respectively. KDM4C-IN-1 is a valuable tool for research applications related to cancer biology and epigenetic regulation.

    1 mg
    $80.00
    5 mg
    $150.00
    All 6 sizes
  • DDP-38003 dihydrochloride
    Cat. No.
    A29329

    DDP-38003 dihydrochloride

    DDP-38003 dihydrochloride is a novel orally bioavailable inhibitor of the lysine-specific demethylase 1A (KDM1A/LSD1) enzyme, demonstrating an IC50 of 84 nM. This compound is valuable for research applications involving epigenetic regulation and modulation of gene expression. Its inhibitory properties make it a pertinent tool for studies in cancer biology and potential therapeutic strategies targeting KDM1A/LSD1 pathways.

    1 mg
    $50.00
    5 mg
    $115.00
    All 6 sizes
  • TAK-418
    Cat. No.
    A29330

    TAK-418

    TAK-418 is a selective inhibitor of the lysine-specific demethylase 1 (LSD1, KDM1A) enzyme, exhibiting an IC50 of 2.9 nM. This compound modulates epigenetic regulation and has demonstrated efficacy in improving symptoms associated with autism in neurodevelopmental disorder models. Its ability to target LSD1 makes it a valuable tool for research into epigenetic mechanisms and potential therapeutic strategies for related disorders.

    1 mg
    $110.00
    5 mg
    $285.00
    All 7 sizes
  • NSC636819
    Cat. No.
    A29331

    NSC636819

    NSC636819 is a competitive and selective inhibitor of the lysine demethylases KDM4A and KDM4B. By targeting these enzymes, NSC636819 may impede the progression of prostate cancer, thereby serving as a valuable tool in cancer research. Its application is particularly relevant for studies aimed at understanding the role of KDM4A/KDM4B in oncogenesis and potential therapeutic strategies for prostate cancer.

    1 mg
    $125.00
    5 mg
    $380.00
    All 4 sizes
  • KDM2B-IN-2
    Cat. No.
    A29332

    KDM2B-IN-2

    KDM2B-IN-2 is a potent inhibitor of the histone demethylase KDM2B, demonstrating an IC50 of 0.021 μM in a KDM2B TR-FRET assay. This compound is utilized in research focused on hyperproliferative diseases, providing insights into epigenetic regulation and potential therapeutic applications. Its high specificity and efficacy make it a valuable tool for studying the role of KDM2B in various biological contexts.

    1 mg
    $50.00
    5 mg
    $120.00
    All 7 sizes
  • KDM5-C49 hydrochloride
    Cat. No.
    A29333

    KDM5-C49 hydrochloride

    Synonyms: KDOAM-20 hydrochloride

    KDM5-C49 hydrochloride is a potent and selective inhibitor of KDM5 demethylases, demonstrating IC50 values of 40 nM, 160 nM, and 100 nM for KDM5A, KDM5B, and KDM5C, respectively. This compound is instrumental for research investigating the role of KDM5 demethylases in cancer biology. Its specificity and inhibitory potency make KDM5-C49 hydrochloride a valuable tool for elucidating the mechanisms of cancer progression and potential therapeutic targets.

    5 mg
    $125.00
    10 mg
    $210.00
    All 5 sizes
  • Seclidemstat mesylate
    Cat. No.
    A29335

    Seclidemstat mesylate

    Synonyms: SP-2577 mesylate

    Seclidemstat mesylate is a potent noncompetitive and reversible inhibitor of the lysine-specific demethylase 1A (LSD1/KDM1A), with a Ki of 31 nM and an IC50 of 13 nM. This compound enhances antitumor immunity in ovarian cancer associated with SWI/SNF complex mutations and demonstrates efficacy in inhibiting viral production, DNA replication, and late gene expression. Seclidemstat mesylate is suitable for research applications in Ewing Sarcoma and other malignancies involving LSD1 modulation.

    5 mg
    $40.00
    10 mg
    $65.00
    All 5 sizes
  • CPI-455 hydrochloride
    Cat. No.
    A29336

    CPI-455 hydrochloride

    CPI-455 hydrochloride is a potent pan-KDM5 inhibitor, exhibiting an IC50 of 10 nM for KDM5A. This compound effectively inhibits KDM5 activity, leading to an increase in global levels of H3K4me3. It has demonstrated the ability to reduce the population of drug-tolerant persister cancer cells across various cancer cell line models subjected to standard chemotherapy or targeted treatments, making it a valuable tool for cancer research and therapeutic development.

    1 mg
    $35.00
    5 mg
    $75.00
    All 6 sizes
  • ALD-52
    Cat. No.
    A29780

    ALD-52

    Synonyms: 1-Acetyl-LSD

    ALD-52 (1-Acetyl-LSD) serves as a prodrug for LSD, primarily targeting serotonin receptors 5-HT1A, 5-HT2A, and 5-HT2C, with binding affinities of 1054, 174, and 10.2 nM, respectively. Upon conversion to LSD, ALD-52 elicits a head-twitch response (HTR) in vivo, demonstrating its psychoactive properties. This compound is valuable in hallucinogen research, providing insights into its pharmacological effects and the underlying mechanisms of serotonergic activity.

    1 mg
    $625.00
    All 1 sizes
  • Iadademstat
    Cat. No.
    A30073

    Iadademstat

    Synonyms: ORY-1001

    Iadademstat is a selective inhibitor of KDM1A (LSD1) that demonstrates potent antileukemic activity. This orally active compound is particularly relevant for research involving relapsed or refractory acute myeloid leukemia. Its mechanism of action and specificity make it a valuable tool for exploring the therapeutic potential of KDM1A inhibition in hematological malignancies.

    5 mg
    $90.00
    10 mg
    $150.00
    All 5 sizes
  • SKLB325
    Cat. No.
    A30097

    SKLB325

    SKLB325 is a selective inhibitor of Jumonji domain-containing 6 (JMJD6) with a binding affinity (KD) of 0.755 μM and an IC50 value of 0.7797 μM. This compound demonstrates significant antitumor activity against ovarian cancer in both in vivo and in vitro models, effectively inducing apoptosis. Additionally, SKLB325 has shown impressive efficacy in renal cell carcinoma (RCC), making it a valuable tool for cancer research and therapeutic exploration.

    1 mg
    $70.00
    5 mg
    $165.00
    All 7 sizes
  • PFI-90
    Cat. No.
    A30183

    PFI-90

    PFI-90 is a selective inhibitor of the histone demethylase KDM3B, effectively inhibiting the action of PAX3-FOXO1. This compound induces apoptosis and promotes myogenic differentiation, leading to increased cell death. PFI-90 exhibits potential antitumor activity, making it a valuable tool for cellular and cancer research studies.

    25 mg
    $30.00
    50 mg
    $50.00
    All 3 sizes
  • Bomedemstat ditosylate
    Cat. No.
    A30233

    Bomedemstat ditosylate

    Synonyms: IMG-7289 ditosylate

    Bomedemstat ditosylate is a potent and irreversible inhibitor of lysine-specific demethylase 1 (LSD1). By inhibiting LSD1, Bomedemstat ditosylate increases methylation levels of H3K4 and H3K9, leading to significant alterations in gene expression. This compound demonstrates notable anti-cancer properties, effectively inhibiting cancer cell proliferation and inducing apoptosis, making it a valuable tool for cancer research and therapeutic development.

    1 mg
    $65.00
    5 mg
    $160.00
    All 6 sizes
  • Methylstat
    Cat. No.
    A30292

    Methylstat

    Methylstat is a potent inhibitor of histone demethylases, effectively suppressing the activity of these enzymes. It demonstrates notable anti-proliferative effects with minimal cytotoxicity, inducing apoptosis and causing cell cycle arrest at the G0/G1 phase. Methylstat enhances the expression of key regulatory proteins such as p53 and p21, and it also inhibits cytokine-induced angiogenesis. This compound serves as a valuable chemical probe for investigating the role of histone demethylation in cancer biology and angiogenesis-related research.

    1 mg
    $30.00
    5 mg
    $155.00
    All 4 sizes
  • S2116
    Cat. No.
    A31081

    S2116

    S2116 is a potent inhibitor of lysine-specific demethylase 1 (LSD1), derived from N-alkylated tranylcypromine (TCP). This compound enhances H3K9 methylation while concurrently promoting H3K27 deacetylation at super-enhancer regions. S2116 effectively induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by downregulating the transcription of NOTCH3 and TAL1 genes, and it has demonstrated significant growth inhibition of T-ALL cells in xenotransplanted mouse models. This reagent holds potential for research applications in cancer biology and epigenetic regulation.

    5 mg
    $490.00
    10 mg
    $815.00
    All 5 sizes
  • S2157
    Cat. No.
    A31244

    S2157

    S2157 is a potent inhibitor of lysine-specific demethylase 1 (LSD1), derived from N-alkylated tranylcypromine (TCP). It enhances H3K9 methylation while concurrently promoting H3K27 deacetylation at super-enhancer regions, contributing to its apoptotic effects in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells through the repression of NOTCH3 and TAL1 gene transcription. Additionally, S2157 demonstrates efficient penetration of the blood-brain barrier, effectively eliminating CNS leukemia in mouse models transplanted with T-ALL cells, making it a valuable tool for cancer research.

    5 mg
    $445.00
    10 mg
    $740.00
    All 5 sizes

Items 126-150 of 170

Added to your cart

View Cart Checkout

    Loading...